Greg Duncan, Virios Therapeutics CEO
September 19, 2022 11:09 AM EDTUpdated 11:28 AM
R&D

Blam­ing Covid-19 for ini­tial da­ta is­sues, an­tivi­ral biotech re­ports PhI­Ib fi­bromyal­gia fail — shares tank

Paul Schloesser

Associate Editor

Close to two years af­ter mak­ing the jump to Nas­daq and rais­ing $30 mil­lion via IPO, Virios Ther­a­peu­tics has failed on a mid-stage study and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times